Robert G Miller
Overview
Explore the profile of Robert G Miller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
2093
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miller R, Zhang R, Bracci P, Azhir A, Barohn R, Bedlack R, et al.
Muscle Nerve
. 2022 Jan;
66(1):39-49.
PMID: 35098554
Introduction/aims: ALS is a heterogeneous disease that may be complicated or in part driven by inflammation. NP001, a regulator of macrophage activation, was associated with slowing disease progression in those...
2.
Cudkowicz M, Lindborg S, Goyal N, Miller R, Burford M, Berry J, et al.
Muscle Nerve
. 2021 Dec;
65(3):291-302.
PMID: 34890069
Introduction/aims: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative illness with great unmet patient need. We aimed to evaluate whether mesenchymal stem cells induced to secrete high levels of neurotrophic...
3.
van den Berg L, Sorenson E, Gronseth G, Macklin E, Andrews J, Baloh R, et al.
Neurology
. 2019 Mar;
92(14):e1610-e1623.
PMID: 30850440
Objective: To revise the 1999 Airlie House consensus guidelines for the design and implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral sclerosis (ALS). Methods: A consensus committee...
4.
Oskarsson B, Moore D, Mozaffar T, Ravits J, Wiedau-Pazos M, Parziale N, et al.
Muscle Nerve
. 2018 Mar;
PMID: 29510461
Introduction: More than 90% of amyotrophic lateral sclerosis (ALS) patients have muscle cramps, but evidence-based treatments have not been available. Methods: A multicenter, double-blind, placebo-controlled crossover trial of mexiletine 150 ...
5.
Miller R, Appel S
Amyotroph Lateral Scler Frontotemporal Degener
. 2017 Sep;
18(sup1):1-4.
PMID: 28872909
ALS is a lethal neurodegenerative disease wherein the diagnosis is often delayed. Our understanding of the pathobiology is slowly expanding, and the number of new genes is rapidly increasing. The...
6.
Lunetta C, Lizio A, Maestri E, Sansone V, Mora G, Miller R, et al.
JAMA Neurol
. 2017 Apr;
74(6):660-667.
PMID: 28384752
Importance: Various factors have been proposed as possible candidates associated with the prognosis of amyotrophic lateral sclerosis (ALS); however, there is still no consensus on which biomarkers are reliable prognostic...
7.
Diana A, Pillai R, Bongioanni P, OKeeffe A, Miller R, Moore D
Cochrane Database Syst Rev
. 2017 Jan;
1:CD006049.
PMID: 28067943
Background: Imbalance of gamma aminobutyric acid (GABA) and related modulators has been implicated as an important factor in the pathogenesis of amyotrophic lateral sclerosis (ALS), which is also known as...
8.
Levine T, Miller R, Bradley W, Moore D, Saperstein D, Flynn L, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2016 Sep;
18(1-2):107-111.
PMID: 27589995
We performed a randomized, double-blind phase I clinical trial for six months on the effects of oral L-serine in patients with ALS. The protocol called for enrollment of patients with...
9.
10.
Burns T, Smith G, Allen J, Amato A, Arnold W, Barohn R, et al.
Muscle Nerve
. 2015 Dec;
53(2):165-8.
PMID: 26662952
No abstract available.